EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Subscribe To Our Newsletter & Stay Updated